Mårten Fernö
11 – 20 of 256
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Disseminated tumour cells from the bone marrow of early breast cancer patients : Results from an international pooled analysis
(
- Contribution to journal › Article
-
Mark
Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer : results from the randomized SweBCG91RT trial
(
- Contribution to journal › Article
- 2020
-
Mark
Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy
(
- Contribution to journal › Article
-
Mark
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer : data from a randomised trial with long-term follow-up
(
- Contribution to journal › Article
-
Mark
Co-localization of CD169+ macrophages and cancer cells in lymph node metastases of breast cancer patients is linked to improved prognosis and PDL1 expression
(
- Contribution to journal › Article
-
Mark
Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery : a long-term follow-up of the SweBCG91-RT randomised trial
(
- Contribution to journal › Article
-
Mark
The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast –long term prognostic significant
(
- Contribution to journal › Article
-
Mark
Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression
(
- Contribution to journal › Article
-
Mark
Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer
(
- Contribution to journal › Article
- 2019
-
Mark
Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial
(
- Contribution to journal › Article